Anhui Baker: Self-developed anti-new crown drug has passed clinical trials and professional review, is waiting for approval to market
Read Time:25 Second
December 20 news, Anhui Baker Pharmaceutical news said, by the enterprise independent development of the new crown treatment of special drugs have passed the relevant clinical trials and professional review, is now waiting for approval to market. It is understood that, as a small molecule inhibitor, monapiravir can interfere with the genetic code of the virus to make errors, so as to achieve the purpose of clearing the virus, mainly for the risk of exposure, mild to moderate new crown pneumonia ambulatory adult patients.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating